Gabapentin Capsule
Product Images NDC 71205-373

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-373). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

A formula image showing the calculation for creatinine clearance (CLCr), including variables for age, weight, sex correction factor, and serum creatinine level.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing mean pain scores over an 8-week period between placebo and gabapentin 3600 mg/day groups. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain score from 0 to 9. The graph indicates a decrease in pain score for the gabapentin group over time versus the placebo group, with labeled 4-week dose titration and fixed dose periods.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph showing mean pain scores over a 7-week period, comparing placebo and gabapentin at dosages of 1800 mg/day and 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show a decrease in pain scores compared to placebo.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. The chart compares placebo (PBO) and gabapentin (GBP) doses with percentage responders: Study 1 - PBO 12%, GBP 3600 mg 29%; Study 2 - PBO 14%, GBP 1800 mg 32%, GBP 2400 mg 34%. Statistical significance (p < 0.01, p < 0.001) is indicated above GBP bars.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

Scatter plot comparing percentage difference by daily dose (mg) across three studies labeled 'a', 'b', and 'c'. The x-axis represents daily dose in mg (600 to 1800), and the y-axis represents percentage difference (2% to 22%). Study a data points are solid black squares, Study b are gray squares, and Study c are white squares with letter annotations next to each point.*

FDA Label Image

71205-373-15 (Gabapentin Fig9)

Gabapentin 100 mg capsules label from Proficient Rx LP. The label indicates the product contains 15 capsules, each with 100 mg of gabapentin USP. It includes the NDC 71205-373-15 and directions to dispense the medication guide separately. The capsule is described as a white, size 3 hard gelatin capsule with specific imprint details. Distributed by Aurobindo Pharma USA, Inc. Made in India, with storage conditions of 20°-25°C (68°-77°F).*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of gabapentin, showing a cyclohexane ring with two substituents: an amino methyl group (CH2NH2) and a carboxymethyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.